Table Filtering
Other Information
Release Statistics Download
GlyCosmos Glycolipids

Glycolipid entries from the LIPID MAPS Structure Database (LMSD).

Source Last Updated
LIPID MAPS Proteome Database (LMSD)
Displaying entries 4276 - 4300 of 6046 in total
Sub Class LM ID Name LipidBank ID KEGG ID PubChem CID ChEBI ID Exact Mass Formula
Diacylglycerophosphoinositolglycans LMGP15010098
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp)-(1-hexadecanoyl-2-tetradecanoyl-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM3(16:0/14:0)
126457466 1268.653008 C57H105O28P
Gangliosides LMSP0601CJ05
  • Galbeta1-3GalNAcbeta1-4(NeuGcalpha2-3)Galbeta1-4Glcbeta-Cer(d18:1/24:0)
44262440 1645.965477 C79H143N3O32
Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glc- (Lacto series) LMSP0504AE00
  • Galalpha1-3(Fucalpha1-2)Galbeta1-3GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer
  • type I B antigen
GSG1171
Diacylglycerophosphoinositolglycans LMGP15010197
  • 2'-O-(alpha-D-Manp)-6'-O-(alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp-1->6-alpha-D-Manp)-(1-hexadecanoyl-2-(9Z,12Z-hexadecadienoyl)-sn-glycero-3-phospho-1'-myo-inositol)
  • PIM5(16:0/16:2(9Z,12Z))
126457565 1616.758658 C71H125O38P
Galalpha1-3Galbeta1-4Glc- (Isoglobo series) LMSP0506BI04
  • Fucalpha1-3GlcNAcbeta1-3Galalpha1-3(GalNAcbeta1-4)Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44261695 1659.981127 C80H145N3O32
Diacylglycerophosphoethanolamine glycans LMGP21010005
  • Am-PE(16:0/18:2(9Z,12Z))
  • N-(1-deoxyfructosyl)-1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphoethanolamine
101027510 877.568032 C45H84NO13P
LMSL03001065
  • 2-octadecanoyl-3-O-(2,4S,6S-trimethyl-2E-hexacosenoyl)-6-O-(2,4S,6S-trimethyl-2E-tetracosenoyl)-2'-O-(2,4S,6S-trimethyl-2E-hexacosenoyl)-4'-O-(2,4S,6S-trimethyl-2E-hexacosenoyl)-alpha,alpha-trehalose
  • PAT18(26:1(2E)(2Me,4Me[S],6Me[S])/24:1(2E)(2Me,4Me[S],6Me[S])/26:1(2E)(2Me,4Me[S],6Me[S])/26:1(2E)(2Me,4Me[S],6Me[S]))
52930902 2254.01574 C144H268O16
LMSL03000812
  • 2-octadecanoyl-3-O-(2,4S,6S-trimethyl-2E-tetracosenoyl)-6-O-(2,4S,6S-trimethyl-2E-tetracosenoyl)-2'-O-(2,4S,6S-trimethyl-2E-hexacosenoyl)-4'-O-(2,4S,6S-trimethyl-2E-docosenoyl)-alpha,alpha-trehalose
  • PAT18(24:1(2E)(2Me,4Me[S],6Me[S])/24:1(2E)(2Me,4Me[S],6Me[S])/26:1(2E)(2Me,4Me[S],6Me[S])/22:1(2E)(2Me,4Me[S],6Me[S]))
52930649 2169.92184 C138H256O16
LMSL03000325
  • 2-O-hexadecanoyl-3-O-(2,4S,6S-trimethyl-2E-pentacosenoyl)-6-O-(2,4S,6S-trimethyl-2E-pentacosenoyl)-2'-O-(2,4S,6S-trimethyl-2E-docosenoyl)-4'-O-(2,4S,6S-trimethyl-2E-hexacosenoyl)-alpha,alpha-trehalose
  • PAT16(25:1(2E)(2Me,4Me[S],6Me[S])/25:1(2E)(2Me,4Me[S],6Me[S])/22:1(2E)(2Me,4Me[S],6Me[S])/26:1(2E)(2Me,4Me[S],6Me[S]))
52930162 2169.92184 C138H256O16
LMSL03000746
  • 2-octadecanoyl-3-O-(2,4S,6S-trimethyl-2E-docosenoyl)-6-O-(2,4S,6S-trimethyl-2E-hexacosenoyl)-2'-O-(2R,4S,6S-trimethyl-3R-hydroxy-tetracosanoyl)-4'-O-(2R,4S,6S-trimethyl-3R-hydroxy-tetracosanoyl)-alpha,alpha-trehalose
  • PAT18(22:1(2E)(2Me,4Me[S],6Me[S])/26:1(2E)(2Me,4Me[S],6Me[S])/24:0(2Me[R],3OH[R],4Me[S],6Me[S])/24:0(2Me[R],3OH[R],4Me[S],6Me[S]))
52930583 2205.94297 C138H260O18
LMSL03000684
  • 2-octadecanoyl-3-O-(2,4S,6S-trimethyl-2E-docosenoyl)-6-O-(2,4S,6S-trimethyl-2E-tetracosenoyl)-2'-O-(2,4S,6S-trimethyl-2E-pentacosenoyl)-4'-O-(2,4S,6S-trimethyl-2E-pentacosenoyl)-alpha,alpha-trehalose
  • PAT18(22:1(2E)(2Me,4Me[S],6Me[S])/24:1(2E)(2Me,4Me[S],6Me[S])/25:1(2E)(2Me,4Me[S],6Me[S])/25:1(2E)(2Me,4Me[S],6Me[S]))
52930521 2169.92184 C138H256O16
LMSL03000493
  • 2-O-hexadecanoyl-3-O-(2,4S,6S-trimethyl-2E-hexacosenoyl)-6-O-(2,4S,6S-trimethyl-2E-hexacosenoyl)-2'-O-(2R,4S,6S-trimethyl-3R-hydroxy-tetracosanoyl)-4'-O-(2,4S,6S-trimethyl-2E-tetracosenoyl)-alpha,alpha-trehalose
  • PAT16(26:1(2E)(2Me,4Me[S],6Me[S])/26:1(2E)(2Me,4Me[S],6Me[S])/24:0(2Me[R],3OH[R],4Me[S],6Me[S])/24:1(2E)(2Me,4Me[S],6Me[S]))
52930330 2215.963705 C140H262O17
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AJ02
  • GalNAcalpha1-3(Fucalpha1-2)Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/18:0)
  • type IV A antigen(d18:1/18:0)
44260237 1765.971352 C82H147N3O37
Gangliosides LMSP0601BA03
  • GD1e(d18:1/20:0)
  • NeuAcalpha2-3Galbeta1-3(NeuAcalpha2-6)GalNAcbeta1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44262174 1865.003381 C86H152N4O39
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AF06
  • Galbeta1-3(GlcNAcbeta1-6)GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/26:0)
44260209 1732.038642 C84H153N3O33
LMSL03000834
  • 2-octadecanoyl-3-O-(2,4S,6S-trimethyl-2E-tetracosenoyl)-6-O-(2,4S,6S-trimethyl-2E-pentacosenoyl)-2'-O-(2,4S,6S-trimethyl-2E-pentacosenoyl)-4'-O-(2,4S,6S-trimethyl-2E-pentacosenoyl)-alpha,alpha-trehalose
  • PAT18(24:1(2E)(2Me,4Me[S],6Me[S])/25:1(2E)(2Me,4Me[S],6Me[S])/25:1(2E)(2Me,4Me[S],6Me[S])/25:1(2E)(2Me,4Me[S],6Me[S]))
52930671 2211.96879 C141H262O16
LMSL03000612
  • 2-O-hexadecanoyl-3-O-(2R,4S,6S-trimethyl-3R-hydroxy-tetracosanoyl)-6-O-(2,4S,6S-trimethyl-2E-hexacosenoyl)-2'-O-(2,4S,6S-trimethyl-2E-hexacosenoyl)-4'-O-(2,4S,6S-trimethyl-2E-docosenoyl)-alpha,alpha-trehalose
  • PAT16(24:0(2Me[R],3OH[R],4Me[S],6Me[S])/26:1(2E)(2Me,4Me[S],6Me[S])/26:1(2E)(2Me,4Me[S],6Me[S])/22:1(2E)(2Me,4Me[S],6Me[S]))
52930449 2187.932405 C138H258O17
Gangliosides LMSP0601FR04
  • NeuAcalpha2-3Galbeta1-4GlcNAcbeta1-3(Galalpha1-3Galbeta1-4GlcNAcbeta1-6)Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/22:0)
44263079 2494.256485 C111H195N5O56
LMSL03000052
  • 2-O-hexadecanoyl-3-O-(2,4S,6S-trimethyl-2E-docosenoyl)-6-O-(2,4S,6S-trimethyl-2E-tetracosenoyl)-2'-O-(2,4S,6S-trimethyl-2E-tetracosenoyl)-4'-O-(2,4S,6S-trimethyl-2E-docosenoyl)-alpha,alpha-trehalose
  • PAT16(22:1(2E)(2Me,4Me[S],6Me[S])/24:1(2E)(2Me,4Me[S],6Me[S])/24:1(2E)(2Me,4Me[S],6Me[S])/22:1(2E)(2Me,4Me[S],6Me[S]))
52929889 2085.82794 C132H244O16
Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glc- (Neolacto series) LMSP0505AD03
  • Fucalpha1-2Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta-Cer(d18:1/20:0)
  • type II antigen(d18:1/20:0)
44260998 1428.870453 C70H128N2O27
Galalpha1-4Galbeta1-4Glc- (Globo series) LMSP0502AE05
  • Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0)
  • SSEA-3 antigen(d18:1/24:0)
44260200 1500.927968 C74H136N2O28
Gangliosides LMSP0601DO06
  • NeuAcalpha2-3Galbeta1-3(Fucalpha1-4)GlcNAcbeta1-3(Galbeta1-4(Fucalpha1-3)GlcNAcbeta1-6)Galbeta1-4Glcbeta-Cer(d18:1/26:0)
  • sLea -Lex(d18:1/26:0)
44262665 2315.249881 C107H190N4O49
Gangliosides LMSP0601AE03
  • NeuAcalpha2-8NeuAcalpha2-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/20:0)
44261998 2027.056206 C92H162N4O44
Gangliosides LMSP0601BX00
  • GalNAc-GD1a(Neu5Ac/Neu5Gc)
  • GalNAcbeta1-4(NeuAcalpha2-3)Galbeta1-3GalNAcbeta1-4(NeuGcalpha2-3)Galbeta1-4Glcbeta-Cer
GSG1036
LMSL03000956
  • 2-octadecanoyl-3-O-(2,4S,6S-trimethyl-2E-pentacosenoyl)-6-O-(2,4S,6S-trimethyl-2E-pentacosenoyl)-2'-O-(2,4S,6S-trimethyl-2E-tetracosenoyl)-4'-O-(2R,4S,6S-trimethyl-3R-hydroxy-tetracosanoyl)-alpha,alpha-trehalose
  • PAT18(25:1(2E)(2Me,4Me[S],6Me[S])/25:1(2E)(2Me,4Me[S],6Me[S])/24:1(2E)(2Me,4Me[S],6Me[S])/24:0(2Me[R],3OH[R],4Me[S],6Me[S]))
52930793 2215.963705 C140H262O17

About Release Notes Help Feedback

Click here to visit the beta site.


International Collaboration

GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.

Acknowledgements

Supported by JST NBDC Grant Number JPMJND2204

Partly supported by NIH Common Fund Grant #1U01GM125267-01


Logo License Policies Site Map

Contact: support@glycosmos.org

This work is licensed under Creative Commons Attribution 4.0 International


GlyCosmos Portal v4.0.0

Last updated: August 19, 2024